logo-loader
viewRhinomed Ltd

Rhinomed Limited in halt on European sales of snoring product

au_europe_map350_55540f8657c7e.jpg

Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to European sales of its Mute over-the-counter snoring product.

The halt will last until the earlier of the announcement being made or the start of trade on Monday, 18th May 2015.

In April, the company expand its Australian wholesale pharmacy distribution footprint with Sigma Pharmaceuticals Limited (ASX:SIP) to include Mute.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Rhinomed Ltd

Price: 0.076 AUD

ASX:RNO
Market: ASX
Market Cap: $12.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences: Dr Weiner announces 'completely novel' approach to...

Harvard Medical School's Dr Howard Weiner, who's also chairman of Tiziana Life Sciences' (LON:TILS)(NASDAQ:TLSA) scientific advisory board, speaks to Proactive London's Andrew Scott after winning a competitive research grant from the NIH (National Institutes of Health) to investigate the drug's...

4 hours, 50 minutes ago

2 min read